Birdwatch Archive

Birdwatch Note

2024-07-31 18:00:29 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING

レプリコンワクチンの治験結果は下記の日本語資料は下記pdfの28P目,資料の24P目等にあり、投稿者の言うような事実は存在しません。 https://web.archive.org/web/20240120232711/https://www.pmda.go.jp/drugs/2023/P20231122002/780009000_30500AMX00282_A100_2.pdf この話は「治験期間3か月間中に死因を問わず"約八千人"中5人のワクチン接種群が死亡し(うちコロナ死1)、プラセボ群は約八千人中16人が死亡(うちコロナ死9)」です なお参加者の17.4%は両群とも60歳以上で自然死亡率の高い高齢者も多数含まれます(下記pdfの35P目、資料の31P目 https://web.archive.org/web/20240120232711/https://www.pmda.go.jp/drugs/2023/P20231122002/780009000_30500AMX00282_A100_2.pdf またワクチン群は3相試験で12.1%が診療を要する有害事象を経験しましたが14.6%のプラセボ群も経験しています↓ https://www.nature.com/articles/s41467-024-47905-1/tables/2

Written by F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D
Participant Details

Original Tweet

Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1818638781769187423

Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.

All Information

  • ID - 1818708327041581130
  • noteId - 1818708327041581130
  • participantId -
  • noteAuthorParticipantId - F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D Participant Details
  • createdAtMillis - 1722448829791
  • tweetId - 1818638781769187423
  • classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
  • believable -
  • harmful -
  • validationDifficulty -
  • misleadingOther - 0
  • misleadingFactualError - 1
  • misleadingManipulatedMedia - 1
  • misleadingOutdatedInformation - 0
  • misleadingMissingImportantContext - 1
  • misleadingUnverifiedClaimAsFact - 1
  • misleadingSatire - 0
  • notMisleadingOther - 0
  • notMisleadingFactuallyCorrect - 0
  • notMisleadingOutdatedButNotWhenWritten - 0
  • notMisleadingClearlySatire - 0
  • notMisleadingPersonalOpinion - 0
  • trustworthySources - 1
  • summary
    • レプリコンワクチンの治験結果は下記の日本語資料は下記pdfの28P目,資料の24P目等にあり、投稿者の言うような事実は存在しません。 https://web.archive.org/web/20240120232711/https://www.pmda.go.jp/drugs/2023/P20231122002/780009000_30500AMX00282_A100_2.pdf この話は「治験期間3か月間中に死因を問わず"約八千人"中5人のワクチン接種群が死亡し(うちコロナ死1)、プラセボ群は約八千人中16人が死亡(うちコロナ死9)」です なお参加者の17.4%は両群とも60歳以上で自然死亡率の高い高齢者も多数含まれます(下記pdfの35P目、資料の31P目 https://web.archive.org/web/20240120232711/https://www.pmda.go.jp/drugs/2023/P20231122002/780009000_30500AMX00282_A100_2.pdf またワクチン群は3相試験で12.1%が診療を要する有害事象を経験しましたが14.6%のプラセボ群も経験しています↓ https://www.nature.com/articles/s41467-024-47905-1/tables/2

Note Ratings

rated at rated by
2024-08-01 18:56:42 -0500 Rating Details
2024-08-01 04:23:57 -0500 Rating Details
2024-08-01 04:13:58 -0500 Rating Details
2024-08-01 03:22:39 -0500 Rating Details
2024-08-01 03:20:24 -0500 Rating Details
2024-08-01 03:13:37 -0500 Rating Details
2024-08-01 02:47:54 -0500 Rating Details
2024-08-01 02:40:07 -0500 Rating Details
2024-08-01 02:39:04 -0500 Rating Details
2024-08-01 02:15:06 -0500 Rating Details
2024-08-01 02:12:44 -0500 Rating Details
2024-08-01 02:03:28 -0500 Rating Details
2024-08-01 02:00:39 -0500 Rating Details
2024-08-01 01:57:54 -0500 Rating Details
2024-08-01 01:34:42 -0500 Rating Details
2024-08-01 01:12:42 -0500 Rating Details
2024-08-01 01:03:17 -0500 Rating Details
2024-07-31 23:28:17 -0500 Rating Details
2024-07-31 23:12:10 -0500 Rating Details
2024-07-31 22:58:25 -0500 Rating Details
2024-07-31 22:10:53 -0500 Rating Details
2024-07-31 21:53:26 -0500 Rating Details
2024-07-31 21:15:20 -0500 Rating Details
2024-07-31 19:15:37 -0500 Rating Details
2024-07-31 18:44:41 -0500 Rating Details
2024-07-31 18:40:34 -0500 Rating Details
2024-07-31 18:02:07 -0500 Rating Details
2024-07-31 17:43:27 -0500 Rating Details
2024-07-31 17:07:22 -0500 Rating Details
2024-07-31 16:56:15 -0500 Rating Details
2024-07-31 16:25:05 -0500 Rating Details
2024-07-31 16:16:00 -0500 Rating Details
2024-07-31 16:15:14 -0500 Rating Details
2024-07-31 14:44:18 -0500 Rating Details
2024-07-31 13:02:29 -0500 Rating Details